The aberrant secretion of visfatin is critical for obesity-associated cancers [17,18] and has been detected in tumor and plasma samples of pancreatic ductal adenocarcinoma, oral squamous cell carcinoma (OSCC), breast cancer, renal cell carcinoma, thyroid cancer and also NSCLC [17,19]. This evidence concerns the gene NAMPT and breast cancer.